In particular, combining nivolumab and 5-FU-based chemotherapy has been prioritized for advanced cancer in palliative therapy settings, with significant improvements in OS (hazard ratio 0.71, 98% confidence interval 0.59–0.86), and the therapeutic effect of these agents was not limited by PD-L1 expression [39, 40]. This evidence concerns the gene CD274 and cancer.